Global Cancer Immunotherapy Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Cancer Immunotherapy Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Cancer Immunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Monoclonal Antibodies
  • 1.4.3 Immune Checkpoint Inhibitors
  • 1.4.4 Immune System Modulators
  • 1.4.5 Cancer Vaccines
• 1.5 Market by Application
  • 1.5.1 Global Cancer Immunotherapy Market Share by Application: 2020 VS 2026
  • 1.5.2 Lung Cancer
  • 1.5.3 Breast Cancer
  • 1.5.4 Colorectal Cancer
  • 1.5.5 Melanoma
  • 1.5.6 Prostate Cancer
  • 1.5.7 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Cancer Immunotherapy Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Cancer Immunotherapy Industry
    • 1.6.1.1 Cancer Immunotherapy Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Cancer Immunotherapy Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Cancer Immunotherapy Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Cancer Immunotherapy Market Perspective (2015-2026)
• 2.2 Cancer Immunotherapy Growth Trends by Regions
  • 2.2.1 Cancer Immunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Cancer Immunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Cancer Immunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Cancer Immunotherapy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Cancer Immunotherapy Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Cancer Immunotherapy Players by Market Size
  • 3.1.1 Global Top Cancer Immunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global Cancer Immunotherapy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Cancer Immunotherapy Market Concentration Ratio
  • 3.2.1 Global Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Cancer Immunotherapy Revenue in 2019
• 3.3 Cancer Immunotherapy Key Players Head office and Area Served
• 3.4 Key Players Cancer Immunotherapy Product Solution and Service
• 3.5 Date of Enter into Cancer Immunotherapy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Cancer Immunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global Cancer Immunotherapy Forecasted Market Size by Type (2021-2026)

5 Cancer Immunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global Cancer Immunotherapy Market Size by Application (2015-2020)
• 5.2 Global Cancer Immunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Cancer Immunotherapy Market Size (2015-2020)
• 6.2 Cancer Immunotherapy Key Players in North America (2019-2020)
• 6.3 North America Cancer Immunotherapy Market Size by Type (2015-2020)
• 6.4 North America Cancer Immunotherapy Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Cancer Immunotherapy Market Size (2015-2020)
• 7.2 Cancer Immunotherapy Key Players in Europe (2019-2020)
• 7.3 Europe Cancer Immunotherapy Market Size by Type (2015-2020)
• 7.4 Europe Cancer Immunotherapy Market Size by Application (2015-2020)

8 China

• 8.1 China Cancer Immunotherapy Market Size (2015-2020)
• 8.2 Cancer Immunotherapy Key Players in China (2019-2020)
• 8.3 China Cancer Immunotherapy Market Size by Type (2015-2020)
• 8.4 China Cancer Immunotherapy Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Cancer Immunotherapy Market Size (2015-2020)
• 9.2 Cancer Immunotherapy Key Players in Japan (2019-2020)
• 9.3 Japan Cancer Immunotherapy Market Size by Type (2015-2020)
• 9.4 Japan Cancer Immunotherapy Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Cancer Immunotherapy Market Size (2015-2020)
• 10.2 Cancer Immunotherapy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Cancer Immunotherapy Market Size by Type (2015-2020)
• 10.4 Southeast Asia Cancer Immunotherapy Market Size by Application (2015-2020)

11 India

• 11.1 India Cancer Immunotherapy Market Size (2015-2020)
• 11.2 Cancer Immunotherapy Key Players in India (2019-2020)
• 11.3 India Cancer Immunotherapy Market Size by Type (2015-2020)
• 11.4 India Cancer Immunotherapy Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Cancer Immunotherapy Market Size (2015-2020)
• 12.2 Cancer Immunotherapy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Cancer Immunotherapy Market Size by Type (2015-2020)
• 12.4 Central & South America Cancer Immunotherapy Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Amgen
  • 13.1.1 Amgen Company Details
  • 13.1.2 Amgen Business Overview and Its Total Revenue
  • 13.1.3 Amgen Cancer Immunotherapy Introduction
  • 13.1.4 Amgen Revenue in Cancer Immunotherapy Business (2015-2020))
  • 13.1.5 Amgen Recent Development
• 13.2 AstraZeneca
  • 13.2.1 AstraZeneca Company Details
  • 13.2.2 AstraZeneca Business Overview and Its Total Revenue
  • 13.2.3 AstraZeneca Cancer Immunotherapy Introduction
  • 13.2.4 AstraZeneca Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.2.5 AstraZeneca Recent Development
• 13.3 Roche
  • 13.3.1 Roche Company Details
  • 13.3.2 Roche Business Overview and Its Total Revenue
  • 13.3.3 Roche Cancer Immunotherapy Introduction
  • 13.3.4 Roche Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.3.5 Roche Recent Development
• 13.4 Bayer
  • 13.4.1 Bayer Company Details
  • 13.4.2 Bayer Business Overview and Its Total Revenue
  • 13.4.3 Bayer Cancer Immunotherapy Introduction
  • 13.4.4 Bayer Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.4.5 Bayer Recent Development
• 13.5 Bristol-Myers Squibb
  • 13.5.1 Bristol-Myers Squibb Company Details
  • 13.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.5.3 Bristol-Myers Squibb Cancer Immunotherapy Introduction
  • 13.5.4 Bristol-Myers Squibb Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.5.5 Bristol-Myers Squibb Recent Development
• 13.6 Eli Lilly
  • 13.6.1 Eli Lilly Company Details
  • 13.6.2 Eli Lilly Business Overview and Its Total Revenue
  • 13.6.3 Eli Lilly Cancer Immunotherapy Introduction
  • 13.6.4 Eli Lilly Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.6.5 Eli Lilly Recent Development
• 13.7 Merck
  • 13.7.1 Merck Company Details
  • 13.7.2 Merck Business Overview and Its Total Revenue
  • 13.7.3 Merck Cancer Immunotherapy Introduction
  • 13.7.4 Merck Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.7.5 Merck Recent Development
• 13.8 Novartis
  • 13.8.1 Novartis Company Details
  • 13.8.2 Novartis Business Overview and Its Total Revenue
  • 13.8.3 Novartis Cancer Immunotherapy Introduction
  • 13.8.4 Novartis Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.8.5 Novartis Recent Development
• 13.9 Pfizer
  • 13.9.1 Pfizer Company Details
  • 13.9.2 Pfizer Business Overview and Its Total Revenue
  • 13.9.3 Pfizer Cancer Immunotherapy Introduction
  • 13.9.4 Pfizer Revenue in Cancer Immunotherapy Business (2015-2020)
  • 13.9.5 Pfizer Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer